Wuming Yan

Chief Scientist Oligonucleotides at Asymchem

Speaker

Dr. Wuming Yan brings over a decade of experience in oligonucleotide CMC (Chemistry, Manufacturing, and Controls), spanning the full development lifecycle from pre-clinical research to commercial manufacturing. He has played pivotal roles in the successful development and regulatory approval of oligonucleotide therapeutics, including Izervay and Spinraza. At Asymchem, Dr. Yan oversees all oligonucleotide programs from early R&D through late-phase development and commercial readiness. He is responsible for building and leading a centralized, collaborative oligo team that serves as a one-stop solution for clients, driving innovation and operational excellence in oligonucleotide manufacturing. Dr. Yan is recognized for his strategic leadership and deep technical expertise in oligo process development, scale-up, and regulatory strategy, making him a trusted partner in advancing oligonucleotide therapeutics from concept to market.